Panbela Therapeutics Beta
Quel est le Beta de Panbela Therapeutics?
Le Beta de Panbela Therapeutics Inc. est 1.27
Quelle est la définition de Beta?
BETA indique si une action est plus ou moins volatile que le marché dans son ensemble. Un bêta inférieur à 1 indique que l'action est moins volatile que le marché, tandis qu'un bêta supérieur à 1 indique que l'action est plus volatile. La volatilité est mesurée par la fluctuation du prix autour de la moyenne.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta des entreprises dans Health Care secteur sur NASDAQ par rapport à Panbela Therapeutics
Que fait Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Entreprises avec beta similaire à Panbela Therapeutics
- Golden Valley Mines a Beta de 1.27
- Sotera Health Co a Beta de 1.27
- Tribune Publishing a Beta de 1.27
- Plutus PowerGen Plc a Beta de 1.27
- Lennar a Beta de 1.27
- Intu Properties Plc a Beta de 1.27
- Panbela Therapeutics a Beta de 1.27
- Hollywood Bowl Plc a Beta de 1.27
- S&T AG a Beta de 1.27
- Synertec a Beta de 1.27
- Hays plc a Beta de 1.27
- Spark Power a Beta de 1.27
- Office Properties Income Trust a Beta de 1.27